LOS ANGELES, March 21, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 2:30 pm Eastern Time.
A webcast of Dr. Singh's presentation will be available both live and on replay. The presentation will be available via webcast at https://www.webcaster4.com/Webcast/Page/392/3641. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of Lion Biotechnologies' presentation will also be accessible via the Investors section of the Company's web site at http://lbio.com/investors/ under "Recent Events."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.lionbio.com.
CONTACT: Investor Relations The Trout Group Gitanjali Jain Ogawa 646-378-2949 email@example.comSource:Lion Biotechnologies, Inc.